

Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024

2024-02-01

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter ended December 31, 2023, on February 22, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on February 22, 2024.

The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. Participants may access the conference call via webcast on the Events & Presentations page of Vir's website at

<https://investors.vir.bio/events-presentations>. A recorded version of the call will be available on the website approximately two hours after the completion of the event and will be archived there for 30 days.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is an immunology company focused on combining cutting-edge technologies to treat and prevent infectious diseases and other serious conditions. Vir has assembled two technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website.

Media

Carly Scaduto

Senior Director, Media Relations

cscaduto@vir.bio

+1 314-368-5189

Investors

Sasha Damouni Ellis

Executive Vice President, Chief Corporate Affairs Officer

sdamouni@vir.bio

Source: Vir Biotechnology, Inc.